Embed Size (px)
Citation preview
Novel Biomarkers for Diagnostics and Drug
R&D – What is industry looking for?
Tom Metcalfe, F. Hoffmann-La Roche AGOntario Genomics Institute, Markers to Markets Workshop, Toronto, June 22nd, 2010
!
"#$%&'#()*
+,)-%./0)/0-.1-0,#$-2*)$)/0'0#./-*)2*)$)/0$-0,)-
2)*$./'&-.2#/#./$-.1-0,)-2*)$)/0)*-'/3-/.0-
/)%)$$'*#&4-0,.$)-.1-5.%,)
6
+,)-2)*$2)%0#7)-.1-0,)-8,'*('%)90#%'&$-:9$#/)$$
;
!"#$%&'#(")*("++,("+-
."/"01%231+4)3#%15
6'5/571')*("++,("+-
85+%2."/"01%)3#%15
9":);"'&/5$5<1"+-
6=>#/?"?)8#>#@1$1%1"+
A"B)C(1D"(+)50)8&#/<")1/)%&")*&#(7#)E/?,+%(B
<
A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B
A call for more effective and safer drugs
=->2)'*$-)0-'&?@-+*)/3$-A.&-A)3@-!BB=C-!-D'E'*.9 )0-'&?@-FGAG@-=HHI
C(,<)3"+>5/+")3#%"G)H
I/#$<"+1'+
B
!B
;B
JB
IB
8#/'"(
6001'#'B J#0"%B
K.7'*0#$
L>M
>'/.1# '7)/0#$
:'4)*
K.7'*0#$
J
A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B
Economic pressures intensify focus on improved benefit-cost ratio
>.9*%)N-O)/0)*$-1.*-A)3#%'*)-'/3-A)3#%'#3@-P11#%)-.1-0,)-G%09'*4@-K'0#./'&-Q)'&0,->0'0#$0#%$-L*.92
R?>?-Q)'&0,%'*)->2)/3#/S@-R>T-:#&&#./$-
!BBB !BBI !B=<
KLMM
NLMM
OMMM
R?>?-Q)'&0,%'*)->2)/3-'$-U-.1-L"8
!BBB !BBI !B=<
KOH
KPH
NMH
V
A"B)C(1D"(+)50)8&#/<")1/)F,()E/?,+%(B)
Step-change needed in Pharma R&D
>.9*%)$N-W"GXO"Y5 "'0'@-8,5AG 3'0'@-8*#%)-Z'0)*,.9$)-O..2)*$-'/'&4$#$@-8,'*('-!B!B
3QC)J>"/?
9":)R5$"',$#()6/%1%1"+)S9R6TU)OV)./)
U)KV)./)KW)
LX
KWWP) NMMV MY MW
NO
NK
I
Z,%,("
!
!
6D5$,%15/)50)R"?1'1/"
6D5$,%15/)50);"'&/5$5<1"+
6D5$,%15/)50)R"?1'1/")[)[)[)#/?)*!8
Progress in therapy driven by new technologies
\2571'+S1["[)*83T
.1521/05(7#%1'+
R5$"',$#(R"?1'1/"
F/'5$5<B
E77,/5$5<B
JB+%"7+).15$5<B;5?#B
R"%#@5$1%"I/#$B]"(+
R5?"(/
R"?1'1/"
\2(#BR1'(52+'5>"
8(1%1'#$)8#("
;(#/+>$#/%#%15/
^#''1/#%15/
R1'(5@15$5<B
KWVM
KYLM J,(<"(B
.$""?1/<
C1++"'%15/
6#($BR"?1'1/"
;5,'&G)J7"$$)Q);#+%"
I/%1_,"R"?1'1/"
KNMM
H
!"#$%&'#(")*("++,("+-
."/"01%231+4)3#%15
6'5/571')*("++,("+-
."/"01%285+%)3#%15
9":);"'&/5$5<1"+-
6=>#/?"?)8#>#@1$1%1"+
9""?)05()&1<&$B)?100"("/%1#%"?)7"?1'1/"+
%&#%)>5+1%1D"$B)17>#'%)>,@$1')&"#$%&
J5'1"%B)#/?)>#B5(+ :1$$)(":#(?)+1</101'#/%)1//5D#%15/
A"B)C(1D"(+)50)8&#/<");5:#(?+)*"(+5/#$1+"?!"#$%&'#(")S*!8T
PHC is key to enabling highly differentiated medicines
=B
`&#%)1+)*"(+5/#$1+"?)!"#$%&'#("aEncompasses many actions to improve patient outcomes
.(5#?"+%)+"/+"
[ P20#('&-'3'20'0#./-.1-,)'&0,%'*)-3)%#$#./$-\QO-('#/0)/'/%)@-(./#0.*#/S@-
2*)7)/0'0#7)-'/3-0,)*'2)90#%-$0)2$]-^'$)3-./-'-2)*$./_$-#/3#7#39'&-
%,'*'%0)*#$0#%$@-,)'&0,%'*)-$0'09$-'/3-2)*$./'&-$#09'0#./?
[ `/%&93)$-0,)-9$)-.1-3#'S/.$0#%$@-%,.#%)-.1-0,)*'24@-%,.#%)-.1-3.$)@-0#(#/S-'/3-
1*)a9)/%4-.1-3.$)
Z5()'57>#/1"+)1/)%&")>&#(7#b@15%"'&)1/?,+%(B):5(4+>#'"
[ 8,'*('-'/3-:#.0)%,@-#/-0,)#*-%'2'%#04-'$-#/39$0*4-()(^)*$-b,#%,-3#$%.7)*@-
3)7)&.2-'/3-('*c)0-#//.7'0#7)-()3#%#/)$-'*)-$0*./S&4-2.$#0#./)3-0.-#(2'%0-'-
%*#0#%'&-2'*0-.1-8)*$./'&#$)3-Q)'&0,%'*)
[ Y/$9*)-0,'0-b)-3)7)&.2-.9*-()3#%#/)$-#/-'-b'4-0,'0-b)-9/3)*$0'/3 b,#%,-
S*.92$-.1-2'0#)/0$-3)*#7)-0,)-(.$0-/)0-^)/)1#0-\)11#%'%4-'/3-$'1)04]-1*.(-0,)-
/.7)&-()3#%#/)$-0,'0-b)-3)7)&.2
==
*"(+5/#$1+"? !"#$%&'#(")#/?)C(,<C1+'5D"(B)#/?)C"D"$5>7"/%
!"#$%&'()#'#*+,-.$/+-,*0$&1$+"#$0-23$0#4#)&('#*+$(-&%#//
C"D"$5>1/<)1//5D#%1D")7"?1'1/"+
C"%"(71/1/<):&1'&)<(5,>+)50)>#%1"/%+)?"(1D")75+%)@"/"01%)0(57)%&")/":)7"?1'1/"
=!
J57")50)%&")>(571+"+)50)*"(+5/#$1+"? !"#$%&'#("
Can we deliver on all of them?
[ `//.7'0#7)-()3#%#/)$-b,#%,-'*)-^)00)*-0'*S)0)3-0.-0,.$)-(.$0-&#c)&4-0.-*)$2./3-'/3-'*)-$'1)*-'/3-(.*)-)11#%'%#.9$-0,'/-%9**)/0-()3#%#/)$-!
[ G/-#/%*)'$)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)-(.&)%9&'*-^'$#$-.1-3#$)'$)-!
[ `(2*.7)3-2'0#)/0-3#'S/.$)$-!
[ `(2*.7)3-2'0#)/0-%'*)-!
[ A.*)-)11#%#)/0-9$)-.1-,)'&0,%'*)-*)$.9*%)$-! d
[ >,.*0)*-'/3-&)$$-)e2)/$#7)-%&#/#%'&-0*#'&$d
=6
J57")50)%&")75+%)7#c5()'&#$$"/<"+)50)?"$1D"(1/<)*"(+5/#$1+"? !"#$%&'#("dd
[ `(2*.7)3-9/3)*$0'/3#/S-.1-,9('/-2'0,.2,4$#.&.S4 '/3-0,)-(.&)%9&'*-^'$#$-.1-3#$)'$)-#$-'-
!"#$%&%" '%#()*+,)#"#)1.*-('c#/S-2*.S*)$$-#/-8QO
[ 8'0#)/0$-/))3-0.-^)-%&.$)&4-#/7.&7)3-f b#0,.90-2'0#)/0$-%./$)/0#/S-0.-^)-#/7.&7)3-#/-%&#/#%'&-
*)$)'*%,-2*.S*'($-'/3-3./'0#/S-^#.&.S#%'&-$'(2&)$-f ^&..3@-09(.9*-0#$$9)-)0%?-(9%,-.1-
0,)-b.*c-#$-/.0-2.$$#^&)
[ :.0,-8,'*('-'/3-"#'S/.$0#%$-#/39$0*4-()(^)*$-(9$0-('c)-'-/9(^)*-.1-%.(2&)e-
.*S'/#E'0#./'&-'/3-&.S#$0#%'&-'3'20'0#./$
[ `//.7'0#7)-*)S9&'0.*4-'22*.'%,)$-'*)-*)a9#*)3-\O*#0#%'&-8'0,-`/#0#'0#7)-)0%?]
[ Ye0)/$#7)-OAY-2*.S*'($-b#&&-^)-*)a9#*)3-#1-2,4$#%#'/$-'*)-0.-('c)-0,)-(.$0-.90-.1-8QO
[ `(2*.7)3-3)%#$#./-$922.*0-$4$0)($-1.*-2,4$#%#'/$-'/3-.0,)*$
[ >#S/#1#%'/0-#//.7'0#./-#/-0,)-"#'S/.$0#%$-('*c)02&'%)-f ^.0,-1*.(-`g"--'/3-#('S#/S-
)a9#2()/0-$922&#)*$-'/3-1*.(-%&#/#%'&-&'^$-'
=;
8&,%"+)#/?)e#??"(+)5/)%&")8(1%1'#$)*#%&-)857>#(#%1D")600"'%1D"/"++G)*(5?,'%)^#$,"G)#/?)%&")f+")50).157#(4"(+)1/)C(,<)C"D"$5>7"/%
[ +,)-#(2)*'0#7)-0.-2*.39%)-,#S,h7'&9)@-#//.7'0#7)-3*9S$-b#&&-#/0)/$#14@-
%*)'0#/S-'-,#S,)*-2)*1.*('/%)-,9*3&)-1.*-/)b-0,)*'2)90#%$?-:'$#%
^#.()3#%'&-$%#)/%)-b#&&-!-+.#)"+&)!,#$%$,&()/%"0,.1(.' b#0,-
0'/0'&#E#/S-2.0)/0#'&-0.-#(2*.7)-7'&9)@-b,)*)'$-()0,.3$-0.-9$)-0,)(-
)11)%0#7)&4-#/-$.+2)$(3(4"50(#&)6%44)(3"43()0".()'4"647?-+,)-^'&'/%)-
^)0b))/-0,)$)-1.*%)$-('4-b)&&-3)0)*(#/)-0,)-$9%%)$$-.*-1'#&9*)-.1-
0,)-3*9S-3)7)&.2()/0-)/0)*2*#$)-.7)*-0,)-/)e0-3)%'3)?
F?-Z..3%.%c@-O&#/?-8,'*(?-'/3-+,)*?-\!BBH]C-IJ@-=@-=!f=;?
=<
857>5/"/%+)50)*!8
Key steps to bringing new value to the practice of medicine
" R/3)*$0'/3-,)0)*.S)/)#04-.1-3#$)'$)$
# "#$%.7)*-'/3-3)7)&.2-.(4(3,#&)/%"0,.1(.'
$ >0*'0#14-2'0#)/0$-b#0,-3#'S/.$0#%-0)$0$
% :9#&3-)7#3)/%)-1.*-^)00)*-^)/)1#0h*#$c-*'0#.
=J
*!8)1+)#%)%&")'5(")50)35'&"g+)/":)#>>(5#'&)%5)C(,<)C1+'5D"(B)#/?)C"D"$5>7"/%
O./1#*('0.*4-8,'$)8.OYe2&.*'0.*4-8,'$)"#$%.7)*4
8,'$)
3"+"#('& 8577"('1#$1]"C"D"$5>
8,'$)-`8,'$)-B 8,'$)-`` 8,'$)-``` W#&#/S8,'$)-`g
A'*c)0+'*S)0
>)&)%0#./
D)'3-
L)/)*'0#./X-
P20#(#E'0#./
"e-&'9/%,X-8.$0h&'9/%,-'$$)$$()/0
:#.('*c)*)e2&.*'0#./
O.(2'/#./-3#'S/.$0#%
1)'$#^#-i-'00*'%0#7)/)$$
3"+"#('&)#++#B ;"'&/1'#$$B)D#$1?#%"?)#++#B 8$1/1'#$$B)D#$1?#%"?)E^C)#++#B
+'#&.*)3-2*)$%*#^#/Si-(./#0.*#/S+'*S)0-#3)/0#1#%'0#./ 8'0#)/0-$)&)%0#./
! !!! !
=V
C(,<)?"D"$5>7"/%)#/?)'57>#/15/)?1#</5+%1')?"D"$5>7"/%)#(")50%"/)/5%)#$1</"?
85/01(7#%5(B)))))))))))))))))))))))*&#+"
*586=>$5(#%5(B)))))))))))))))))))))
*&#+"
C1+'5D"(B*&#+"
*&#(7
#)3QC)>(5'"++)
Q)?"'1+15/)>51/%+
8$1/1'#$)8#/?1?#%")J"$"'%15/
6/%(B)E/%5)!,7#/ Z1$1/<
.157#(4"()C1+'5D"(B)
Q)C
"D"$5>7"/%
.157#(4"()8#/?1?#%"+))))))))))))))))C1+'5D"(B
;"'&/1'#$b))))))))))))))))))8$1/1'#$))))))))))))))))))))))
^#$1?#%15/
E^C)C"D"$5>7"/%
.157#(4"()8#/?1?#%"+)C1+'5D"(BN-K.7)&-,42.0,)$#$h L)/)*'0#/S-$0*'0)S4
;"'&/1'#$b)8$1/1'#$)^#$1?#%15/-)Q42.0,)$#$-#$-^)#/S-7''0)3-X-)/0)*#/S-
%&#/#%'&-7''0#./
E^C)C"D"$5>7"/%N-:#.('*c)*-'$$'4-#/-
%&#/#%'&-7''0#./
=I
35'&"g+)3"+"#('&)#/?)6#($B)C"D"$5>7"/%)R5?"$
Bringing the right disciplines together at the centre of drug discovery & early development
;(#/+$#%15/#$)R"?1'1/"
!"#$%&'()*+)#',-
^1(5$5<BR"%#@5$1')C1+"#+" E/0$#77#%15/F/'5$5<B
C1+'5D"(B)#/?);(#/+$#%15/#$)I("#+
R5?"$1/<)Q)J17,$#%15/
./'0)*+)1'#'%-2&34'-,
.157#(4"(+
5)6)03-$*$%%6#
JB+%"7).15$5<B
7-+)/#$3-+*1%&86)9'$:
!1<&"()_,#$1%B)
'$1/1'#$)
'#/?1?#%"+
E7>(5D"?)
,/?"(+%#/?1/<)
50)?1+"#+"
."%%"()
'#/?1?#%")
@157#(4"(+
89JC1+"#+"
=H
.157#(4"(+
Essential to enabling translational medicine and drug development
[ f/?"(+%#/?1/<)>#%&:#B+)#/?)7"'&#/1+7+\)?S?-0'*S)0$@-(.&)%9&'*-()%,'/#$($-'/3-2'0,.2,4$#.&.S4]-
[ E7>(5D"?)?"'1+15/)7#41/<)1/)3QC\)?S?-0..&$-1.*-2*.1#&#/S-0'*S)0$@-%.(2.9/3$@-8"-'/3-$'1)04-
A'*c)*$]
[ C(1D"(+)05()>&#(7#'5?1#</5+%1')?"D"$5>7"/%\)/,'/%#/S-*)$2./$)-*'0)$@-#(2*.7#/S-^)/)1#0X*#$c-*'0#.@-
%.(2'/#./-3#'S/.$0#%$]
!B
.157#(4"(+)#/?)*&#(7#'5?1#</5+%1'+Biomarkers are essential tools in modern drug development and key to Personalised Healthcare
Disease
Biomarkers
• Patient risk
• Early detection
• Prognosis
• Monitoring/ Recurrence
Pharmacodiagnostic
Biomarkers
• Treatment eligibility
• Response prediction
• Safety and Efficacy
perspective
Pharmacological
Biomarkers
• Pharmacodynamic markers
• Pharmacokinetic markers
• Mechanism of action markers
Biomarkers
!=
h,#$101'#%15/)50)/5D"$)@157#(4"(+
8$1/1'#$)^#$1?1%B
[ R/3)*$0'/3-'/3-'%%.9/0-1.*-^#.&.S#%'&-
7'*#'^#
[ `/0)*2*)0-7'*#'^#-#/-0,)-%./0)e0-.1-
#/0)/3)3-9$)
[ O&#/#%'&-90#-)$0'^&#$,)3-^4-9$#/S-'-
7'-^#.('*c)*-#/-0,)-%&#/#%
I/#$B%1'#$)^#$1?1%B
[ R/3)*$0'/3-7'*#'^#-#/-0,)-()'$9*#/S-
$4$0)(
[ D#(#0X%./0*.&-$.9*%)$-.1-7'*#'^#
;&")1/%"/?"?),+")50)%&")@157#(4"()+&#>"+)7,'&)50)%&")?"D"$5>7"/%):5(4)#/?)/""?+)%5)@")?"'1?"?)#%)#/)"#($B)+%#<"
+,)-GOOY 1*'()b.*c-\G/'&40#%'&-7'#04@-O&#/#%'&-7'#04@
O&#/#%'&-90#@-Y0,#%'&@-D)S'&-'/3->.%#'&-%./$#3)*'0#./$]@-#$-'22&#%'^&)
0.-1.*($-.1-(.&)%9&'*-3#'S/.$0#%$-'/3-^#.('*c)*
!!
`&#%)#@5,%)7,$%1>$")7#(4"()>#/"$+a
G33#0#./'&-%.(2&)e#04N
[ Y'%,-()(^)*-.1-0,)-2'/)&-'33$-'/-'33#0#./'&-$.9*%)-.1-2.0)/0#'&-)**.*-h0*'3)h.11$-#/-'33)3-$)/$#0#7#04-'0-2.0)/0#'&-%.$0-0.-$2)%#1#%#04-(9$0-^)-('3)
[ O./0*.&-1.*-#/0)*1)*)/%)-^)0b))/-)'%,-#/3#7#39'&-()(^)*-.1-0,)-2'/)&
[ `/%*)'$)3-%./$0*'#/0$-./
f >'(2&)-%.&&)%0#./@-2*)2'*'0#./-'/3-$0.*'S)
f A)'$9*)()/0-$4$0)(
f O./0*.&@-%'&#^*'0#./@-$0'/3'*3#E'0#./-%./%)20$
[ O.&&)%0#/S-3'0'-./-0,)-^#.('*c)*-2'/)&_$-2)*1.*('/%)-#/-0,)-#/0)/3)3-$)00#/S@-'22&#)3-0.-0,)-#/0)/3)3-%&#/#%'&-2.29&'0#./-)$$)/0#'&
!6
.157#(4"()C1+'5D"(B)Q)C"D"$5>7"/%
Analytical validation/quality needs differ according to intended use
E^C)C"D"$5>7"/%;"'&/1'#$)b)
8$1/1'#$)D#$1?#%15/.157#(4"()8#/?1?#%"+)C1+'5D"(B
95[)50).157#(4"(+)#/?)I++#B+
h,#$1%B)("_,1("7"/%+)S'$1/1'#$)#/?#/#$B%1'#$)D#$1?1%B)50)#++#B+T
!;
Z5',+)5/),/?"(+%#/?1/<)?1+"#+")#%)%&")75$"',$#()$"D"$Increased effort to understand disease biology and translationalmedicine to achieve PHC
"[<[))F/'5$5<B-)
[ `")&#D")17>(5D"?)>(5'"++"+)05()>#%1"/%)+#7>$")'5$$"'%15/
f '()/3)3-`/1.*()3-O./$)/0@-('/3'0.*4-$'(2&)-%.&&)%0#./-
$0*'0)S#)$
[ `")&#D")1/'("#+"?)5,()"005(%)1/)>("'$1/1'#$)>(501$1/<
f #/%*)'$)3-3)20,-.1-2*)%&#/#%'&-2*.1#&#/S-./-%&9$0)*$-.1-
(.&)%9&)$ \)?S?-'/0#h'/S#.S)/)$#$]-#/%&93#/S-('*c)0)3-.*-
&'0)-$0'S)-(.&)%9&)$
[ `")&#D")"=>#/?"?)5,()>#(%/"(+&1>+):1%&)#'#?"71')'577,/1%1"+
f +*'/$&'0#./'&-A)3#%#/)-Q9^-#/->#/S'2.*)-.2)*'0#./'&#E)3 #/-
)'*&4-!B=B
!<
[ 5#$c$-'/3-^)/)1#0$-*)&'0)3-0.-jY(2#*#%-G22*.'%,_
f 2*)$9(20#7)-0*)'0()/0-7)*$9$-0)$0-'/3-0*)'0
f /'09*)-.1-#&&/)$$-\'%90)@-)h0,*)'0)/#/S]-'/3-0*)'0()/0-'&0)*/'0#7)$
[ +,)*'2)90#%-*)$2./$)-*'0)
f 5)&'0#7)&4-,#S,-\kJBU]-.*-&.b-\l-6BU]?
[ 5)&'0#7)-%.$0$
f 0.0'&-%.$0-.1-'%a9#*#/S-0)$0-#/1.*('0#./-\0#()-'/3-(./)4]-7)*$9$ $'7#/S$-1*.(-0)$0#/S
f 2)*%)#7)3-'33#0#./'&-7'&9)-39)-0.-*)39%0#./-.1-2'0#)/0-9/%)*0'#/04
[ 5)&'0#7)-2*)3#%0#7)-7'&9)
f ,.b-b)&&-3.)$-0,)-0)$0-#/1.*(-%&#/#%'&-3)%#$#./-('c#/Sd
[ `$$9)$-*)&'0)3-0.-('*c)0-'%%)20'/%)X2*'%0#%'
f 0)$0-2&'01.*(-'7'#&'^#@-2,4$#%#'/-)39%'0#./-'/3-'%%)20'/%)-)0%?
8$1/1'#$),%1$1%B)50)("+>5/+")>("?1'%15/5&'#$6#.$1,%+&-/
!J
J57"%17"+)+%#(%1/<)>51/%)05()("+>5/+")7#(4"(+)5@D15,+[[MDM2 Biomarker Program
[ A"A! '/0'S./#$0$-b#&&-&#c)&4-/.0-^)-^)/)1#%#'&-1.*-2'0#)/0$-b#0,-09(.*$-(90'0)3-1.*-2<6\'22*.e-<B-U-.1-,9('/-09(.*$]
[ 8'0#)/0-$0*'0#1#%'0#./-^4-2<6-S)/)-$0'09$-*)a9#*)3-0.-#3)/0#14-2.0)/0#'&-*)$2./3)*$
p53 AmpliChip
Roche RMD
Roche Diagnostics developing a test
platform for p53 resequencing
MDM2 inh binds to MDM2
• MDM2 is the master regulator of p53
• Antagonists of p53-MDM2binding can activate the p53 pathway and restore cell cycle arrest and apoptosis
min the p53 binding
!V
;#(<"%1/<).3IZ R,%#%15/+)1/)8#/'"(
One promising early phase example
8)94%#):#!"4)!6NJVV=-\!BB<]-A-:))*'( (&),4;<)9,#!(.)9(44)JN6=6-\!BB;]-AF-L'*/)00-'/3-5-A'*'#$-
[ ;5<= <"/")7,%#%15/+)?"%"'%"?)1/)iVH)50)#$$)'#/'"(+
f R2-0.-VBU-.1-('&#S/'/0-()&'/.('$
f R2-0.-<6U-.1-2'2#&&'*4-0,4*.#3-%'*%#/.('$
f R2-0.-=<U-.1-%.&.*)%0'&-09(.*$
[ R5+%)'5775/)7,%#%15/)@B)0#(-)^PMM6)1/)"=5/)KL
f n-VBU-()&'/.('$@-0,4*.#3-'/3-%.&.*)%0'&-%'/%)*$--
b#0,-(90'0)3-=>?@
5GW-'%0#7'0)$-0,)-AG8M-$#S/'&#/S-2'0,b'4
:5GW-%'/-^)-'%0#7'0)3-^4-'-$#/S&)-(90'0#./-\gJBBY] *e\OMXN N-K.7)&-$('&&h(.&)%9&)-
#/,#^#0.*-1*.(-8&)ee#c./
85C=)/""?N-+'a('/o 8O5h^'$)3-
gJBBY (90'0#./-3)0)%0#./
!I
C"01/1/<)("+>5/+")1/)>#%1"/%+):1%&)3&",7#%51?)I(%&(1%1+
3"+>5/+")7"#+,("?)@B)'57>5+1%")+'5("+
f I83)S17>(5D"7"/%)/5%)#'%1D1%BT
[ GO5!B-f '-!BU-#(2*.7)()/0-#/-+FO-'/3->FO-'/3-#/-6-.1-0,)-1.&&.b#/S-
f 8'0#)/0-S&.^'&-'$$)$$()/0
f 8,4$#%#'/$-S&.^'&-'$$)$$()/0
f 8'0#)/0$-'$$)$$()/0-.1-2'#/
f ")S*))-.1-3#$'^#-
f D)7)&-.1-'%90)-2,'$)-*)'%0'/0$
f CIJ)S17>(5D"7"/%)#/?)#'%1D1%BT
[ `/%&93)$-'*0#%9&'*-#/3)e@->FO@-Y>5@-8'0#)/0-S&.^'&-'$$)$$()/0
f L..3-*)$2./$)-"G>-l!?;C-"k=?!
f K./h*)$2./3)*-"G>-k6?VC-"lB?J
f C100"("/%)%&"(#>1"+)7#B)>(5?,'")?100"("/%)"00"'%+)5/)%&")'57>5/"/%+)50)#)'57>5+1%")+'5(")j #/?)%&"("05(")5/)%&")7"#+,("7"/%)50)("+>5/+"
!H
C1+'5D"(1/<)#/?)1/%"<(#%1/<)/5D"$)("+>5/+")7#(4"(+)1/%5)?(,<)?"D"$5>7"/%
O,'&&)/S)$m
[ O.**)&'0#./-.1-/.7)&-('*c)*$-b#0,-*)$2./$)-*)a9#*)$-0,'0-0,)*)-^)-$911#%#)/0-*)$2./3)*$-#/-)'*&4-3)7)&.2()/0
[ ".-b)-,'7)-0,)-*#S,0-*)$2./$)-2,)/.042)d-)?S?-09(.*-*)$2./$)-7)*$9$-$9*7#7'&
[ ".)$-0,)-('*c)*-3)1#/)-*)$2./$)-\2*)3#%0#7)]-.*-'-3#11)*)/0-%.9*$)-.1-3#$)'$)-\2*.S/.$0#%]-.*-^.0,d
[ Q'7)-b)-S.0-'%%)$$-0.-0,)-*#S,0-042)-.1-%&#/#%'&-$'(2&)$d-\'/3-,'7)-0,)4-^))/-$0.*)3-%.**)%0&4m?]
[ Q42.0,)$#$-1*))-'22*.'%,)$-\)?S?-ZLG>@-0*'/$%*#20.(#%$]-()'/-0,'0-b)-3./_0-,'7)-0.-$0'*0-b#0,-'-,42.0,)$#$@-^90-b#&&-&)'3-0.-('/4-1'&$)-p7)_$
[ A'4-.10)/-*)$9&0-#/-$0*'0#1#%'0#./-,42.0,)$)$-^)#/S-3)7)&.2)3-2.$0-#/#0#'&-&#%)/$#/S-.1-(.&)%9&)m?
6B
+ response - response
+ test true positive & false positive
- test ' false negative true negative
Efficacy marker: High sensitivity + adverse event - adverse event
+ test true positive ' false positive
- test & false negative true negative
Safety marker: High specificity
+ response - response
+ test true positive ' false positive
- test & false negative true negative
Efficacy marker: High specificity + adverse event - adverse event
+ test true positive & false positive
- test ' false negative true negative
Safety marker: High sensitivity
Less serious illness: don’t prescribe inappropriately
Serious illness: don’t withhold therapy inappropriately
E/%"/?"?),+")50)@157#(4"()?"%"(71/"+)("_,1("?)>"(05(7#/'"!-,0#$&11/$7*$/#*/7+747+.$4#-/2/$/(#%717%7+.
6=
*&#(7#'5?1#</5+%1')%"+%)("_,1("7"/%+
[ 3"$1#@$")%"+%+f &.b-7'*#'^#-h *.^9$0-'/3-*)2*.39%#^&)
f ,#S,&4-2*)3#%0#7)
[ 6#+B)%5)#?71/1+%"(f b,.&)-^&..3X$)*9(-h ^#.2$4d
f *'2#3-0)$0-09*/'*.9/3
f 7'&9)-.1-0)$0-#/1.*('0#./-.90b)#S,$-'%a9#$#0#./-%.$0$-\0#()X%.$0X#/7'$#7)/)$$]
[ `1?"$B)#D#1$#@$"f '7'#&'^#-.1-0)$0-/.-,#/3*'/%)-0.-('*c)0#/S-.1-3*9S
f 0)$0#/S-2&'01.*(-b#0,-('/4-2&'%)()/0$-.*-&.b-'%a9#$#0#./-%.$0$
[ 85/',(("/%f '22*.7'&-.1-0)$0-%./%9**)/0-b#0,-3*9S-'22*.7'&
6!
3"_,1("7"/%+)50)#)*&#(7#'5?1#</5+%1')>#(%/"(
[ `/0)*/'0#./'&-2*)$)/%)
f b#3)-%.(()*%#'&-*)'%,
f *)S9&'0.*4-/)0b.*c-1.*-W"GXOYXF'2'/X>"G
[ G%%)$$-0.-^*.'3-*'/S)-.1-0)%,/.&.S#)$
f )e2)*#)/%)-b#0,-*)a9#*)3-0)$0#/S-2&'01.*(
f `8-^'**#)*$-/.-2*.^&)(-f 1*))3.(-0.-.2)*'0)
[ D'*S)-#/$0'&&)3-^'$)-.1-$4$0)($
[ L..3-0*'%c-*)%.*3-#/-3)7)&.2()/0X*)S9&'0.*4-'11'#*$
[ K.-#$$9)$-b#0,-%.(2)0#0#7)-2*.39%0$X*)&'0#./$,#2$
66
+,)-2)*$2)%0#7)-.1-0,)-"#'S/.$0#%$-:9$#/)$$
6;
J5,('"+)50)95D"$)E^C)R#(4"(+)#/?)I$<5(1%&7+Mix of internal programs, collaborative programs and in-licensing
35'&")*&#(7#@157#(4"()>(5<(#7+ X(? >#(%B)*&#(7#
'57>#/15/)?1#</5+%1'+
E/2&5,+")7#(4"()?1+'5D"(B)>(5<(#7+
E/2$1'"/+1/<)0(57)#'#?"71#G)@15%"'&)5()5%&"()?1#</5+%1')'57>#/1"+
85$$#@5(#%1D")>(5<(#7+):1%&)#'#?"71#)#/?)@15%"'&
6<
e#(<")*5(%05$15)50);"+%1/<)*$#%05(7+Maintenance of existing test portfolio requires considerable investment
'5@#+k IBBB-
'/'&4E)*-$)*#)$
'5@#+k ;BBB-
'/'&4E)*-$)*#)$
'5@#+k JBBB-
'/'&4E)*-$)*#)$
JB+%"7)*5(%05$15)1/)%&")J"(,7)`5(4)I("#)50)35'&")*(50"++15/#$)C1#</5+%1'+
6J
95D"$)E^C)#++#B+)4"B)05()%&")E^C)E/?,+%(BTesting Efficiency and Medical Value key drivers of innovation & growth
E/+%(,7"/%E//5D#%15/
R"/,.("#?%&
`5(40$5:Q)E;
;"+%1/<
6001'1"/'B
R"?1'#$
^#$,"
C"D"$5>9":
85/%"/%
I>>$B85/%"/%)05(9":)f+"+
C"'"/%(#$1]";"+%1/<
6V6V
R"?1'#$)^#$,"
Finding & driving new content addressing high medical needs
Z5',+)5/-)
[ &)7)&-.1-9/()0-()3#%'&-
/))3
[ 3#$)'$)-^#.&.S4-
9/3)*$0'/3#/S
[ ,)'&0,h)%./.(#%-7'&9)
d :&#%)1%)%#4"+
=? ")7)&.2()/0-i-#(2&)()/0'0#./-.1-%*.$$h:G-3#$)'$)h'*)'-$0*'0)S#)$
!? `(2&)()/0'0#./-.1-'-$4$0)('0#%-2*.%)$$-0.-)11#%#)/0&4-'%%)$$-/)b %./0)/0
[ `3)/0#1#%'0#./-i-1#/3#/S@-'%%)$$#/S-i-$)%9*#/S-"e-`8XW+P@-3)7)&.2#/S-
'$$'4$@-1'$0-i-#/1.*()3-3)%#$#./h('c#/S
C"D"$5>9":
85/%"/%
I>>$B85/%"/%)05(9":)f+"+
>)+'136*?36")
6I6I
;("#%7"/%)R#>+
I''"++)R"?1#$)^#$,").157#(4"(+)05()F/'5$5<B
Two key focus areas & approaches
l[ +*)'0()/0-$)&)%0#./
[ 5)$2./$)-2*)3#%0#./
[ >%*))/#/S
[ "#'S/.$#$
[ 8*.S/.$#$
[ 8*)3#%0#./
[ A./#0.*#/S
C1#</5+%1'+
857>#/15/C1#</5+%1'+
R5$"',$#()*#%&:#B+
>)+'136*?36")
6H
31+4)I++"++7"/%
F>>5(%,/1%B)#++"++7"/%
Unmet needs in many areas of patient management
8*)3#$2.$#0#./-1.*-3)7)&.2#/S-
3#$)'$)
+,)*'24-'3'20'0#./
8'0#)/0->0*'0#1#%'0#./-X-+,)*'24->)&)%0#./
J'(""/1/<b)C1#</5+1+ *(5</5+%1' *("?1'%1D" R5/1%5(1/<
Y'*&4-3)0)%0#./
8*)3#%0-2*.^'^&)-
3#$)'$)-%.9*$)
8*)3#%0-&#c)&4-*)$2./$)-0.-'-
3*9S
A./#0.*-)11#%'%4X-*)%9**)/%)
Q)'&0,4 G$4(20.('0#%-3#$)'$)
O,*./#%-3#$)'$)-O9*)3
>4(20.('0#%-3#$)'$)
;B
J%(#%"<1')*(15(1%1]#%15/)50)Z5',+)E/?1'#%15/+8,9&-$:-7+#-7,$
[ A'#/-1.%9$-#$-./-'*)'$-0,'0-'*)-('q.*-%./0*#^90.*$-0.-(.*^#3#04-'/3-
(.*0'-#/-3)7)&.2)3-%.9/0*#)$ $9%,-'$-O'*3#.7'$%9&'*-"#$)'$)$@-
A)0'^.&#%-"#$.*3)*$-)?S?-"#'^)0)$-i-K)2,*.2'0,4@-P/%.&.S4@-
P$0).3)S)/)*'0#7) "#$.*3)*$-'/3-OK>-3#$)'$)
[ G*)'$-b,)*)-#/h7#0*.-&'^.*'0.*4-0)$0$-\$)*9(-'$-$'(2&)-.1-%,.#%)]-
'*)-%./$#3)*)3-0.-^)-('q.*-3#'S/.$0#%-%./0*#^90.*$
[ G%0#./'^# .1-0,)-0)$0-*)$9&0-\b#&&-#0-&)'3-0.-'-%,'/S)-#/-2'0#)/0--
%'*)]
[ >0*'0)S#%-1#0-0.-)e#$0#/S-0)$0-()/9
;=
R#c5()h,"+%15/+)05()9":)R#(4"()))))))))))))))))))))#/?)I$<5(1%&7)C"'1+15/+)
`$-0,)-('*c)*X'&S.*#0,(-'$1/1'#$$B),+"0,$d-`/0)/3)3-9$)-b.*c#/S-,42.0,)$#$-'/3-'7'#&'^&)-)7#3)/%)-\)e#$0#/S-3'0'-.*-3'0'-0.-^)-S)/)*'0)3-
0.S)0,)*-b#0,-$%#)/0#1#%-%.&&'^.*'0#./$]@-#/%&93#/S-'$$)$$()/0-.1-
%.(2)0#0#7)-3#'S/.$0#%-0)%,/.&.S#)$
K[
".)$-0,)-7#(4"% +1]" q9$0#14-0,)-#/7)$0()/0-.*-2*.7#3)-%.(2)0#0#7)-
'37'/0'S)-#1-2*.39%0-3)7)&.2()/0-%'/-/.0-^)-q9$0#1#)3-'$-$0'/3h'&./)d
N[
G*)-0,)-0)$0$-%"'&/1'#$$B 0"#+1@$" ./-5.%,)-2&'01.*($dX[
`$-0,)-0)%,/.&.S4-%.7)*)3-^4->#%"/%S+TdO[
`$-0,)*)-#''"++)%5)#)$1'"/+" '/3-'0-b,'0-%.$0$dL[
Q.b-^#S-'*)-0,)-*)a9#*)3-"005(%+)05()7#(4"%)?"D"$5>7"/%d\%&#/#%'&-3)7)&.2()/0@-*)S9&'0.*4-'22*.7'&-'/3-('*c)0-3)7)&.2()/0-%.$0$]
P[
;!
e1D"(
C1+"#+"+
e1D"(
C1+"#+"+
R"%#@5$1')JB/?(57"R"%#@5$1')JB/?(57"
F/'5$5<BF/'5$5<B
e1D"(2Z1@(5+1+
9IJ!b9IZeC
e1D"(2Z1@(5+1+
9IJ!b9IZeC
!88!88
81((&5+1+9"'(5+1+
81((&5+1+9"'(5+1+
8#(?15$5<B
I%&"(5+'$"(5+1+
8#(?15$5<B
I%&"(5+'$"(5+1+
9">&(5>#%&B9">&(5>#%&B
C1#@"%"+C1#@"%"+
J%(54"S;(#,7#T
J%(54"S;(#,7#T*,$75/#(B
C1+"#+"+
*,$75/#(BC1+"#+"+^#+',$#()
3"75?"$$1/<
J">+1+J">+1+
*(5+%#%"*(5+%#%"
FD#(B*"$D1')R#++
FD#(B*"$D1')R#++
E/0[)C1+[E/0[)C1+[
9":)R#(4"()J"#('&)Z5',+)05()*(5%"1/)#/?)R"%#@5$1').157#(4"(+
;6
J'5>1/<)50)8#(?15^#+',$#( C1+"#+"
>("?1+>5+1%15/%&"(#>B
+%(#%101'#%15/?1#</5+1+ 75/1%5(1/<
>("D"/%15/G)75?10B1/<)
50)(1+4)0#'%5(+
;&")/""?)05()
%"+%1/<
K.-2)*%)20#^&)-
)7#3)/%)-
.1-3#$)'$)
K.-2)*%)20#^&)-
)7#3)/%)-
.1-3#$)'$)
K.-$4(20.($-
.1-3#$)'$)@-
3#$2&'4-.1-*#$c-1'%0.*$-
\$0'S)-G]
K.-$4(20.($-
.1-3#$)'$)@-
3#$2&'4-.1-*#$c-1'%0.*$-
\$0'S)-G]
>4(20.($-.1-
O,*./#%-3#$)'$)-
\$0'^&)-'/S#/'@-
$,.*0/)$$-.1-^*)'0,]
>4(20.($-.1-
O,*./#%-3#$)'$)-
\$0'^&)-'/S#/'@-
$,.*0/)$$-.1-^*)'0,]
>4(20.($-.1-G%90)-
3#$)'$)-
\O,)$0-8'#/@->.:@-
>0*.c)@-G%90)-D#(^-
"#$%.(1.*0-\OD`]]
>4(20.($-.1-G%90)-
3#$)'$)-
\O,)$0-8'#/@->.:@-
>0*.c)@-G%90)-D#(^-
"#$%.(1.*0-\OD`]]
8.$0h'%90)@-/))3-1.*-
$9*7)#&&'/%)X1.&&.b-92
8.$0h'%90)@-/))3-1.*-
$9*7)#&&'/%)X1.&&.b-92
8*.S*)$$#./-.1-G0,)*.$%&)*.$#$ $)%./3'*4 %.(2&#%'0#./$@-
*#%1"/%)+"%%1/<
C5'%5(g+)5001'"
85/+,7"()l)>&B+1'1#/a
!5+>1%#$)6Cb88bE8f
I7@,$#%5(Bb)C#B'#("
C1+"#+")
+%#<"+
C5'%5(g+)5001'"
;;
.157#(4"()C"D"$5>7"/%)j 3"_,1("?)8#>#@1$1%1"+
Significant challenges to establishing clinically viable and useful biomarkers
L)/)*'0#./-.1-'-^#.('*c)*-,42.0,)$#$
")7)&.2-2*.0.042)-'$$'4
`3)/0#1#%'0#./-.1-%'/3#3'0)-('*c)*$
C1+'5D"(B O&#/#%'&-7''0#./-.1-%'/3#3'0)-('*c)*$-9$#/S-'$$'4
G$$'4-*)1#/)()/0-i-3)7)&.2()/0-`g"-0)$0
5)S9&'0.*4-0)$0-'22*.7'&
^#$1?#%15/bh,#$101'#%15/
"#$0*#^90#./-0.-&'^.*'0.*#)$
G93#0#/S-1.*-*)$9&0-%./$#$0)/%4
8577"('1#$1]#%15/O&#/#%#'/X-D'^-)39%'0#./
;<
Feasibility Development Implementation SalesAnalysis
W)'$#^#-'22*.7)3
A'*c)0-'/3-%9$0.()*-*)a9#*)()/0$-
'/'&4E)3
:9$#/)$$-*)a9#*)()/0$-
%./$#3)*)3
+)%,/#%'&-1)'$#^#-3)(./$0*'0)3
8*.39%0-'/3-2*.q)%0-*#$c-'$$)$$)3
D)S'&-'/3-*)S9&'0.*4-#$$9)$
%./$#3)*)3
K)S.0#'0)3-$2)%#1#%'0#./$
")0'#&)3-2*.q)%0-2&'/
8*.1#0'^#-'$$)$$)3
W9/%0#./'&-(.3)&-")7)&.2()/0-
*)1?-&.0-'22*.7)3-
\3)$#S/X2)*1.*('/%)]
8*.0.042)XA'$0)*-2#&.0-&.0-
'22*.7)3 \3)$#S/-'/3-
2)*1.*('/%)]
>2)%#1#%'0#./$-%./1#*()3-\#1-
/))3)3-^4-%9$0.()*$]
5p"-3)7#%)-('$0)*-*)%.*3-
2*.39%0-3)1#/)3@-3)1#/)3-
('0)*#'&$@-$922&4--%,'#/-'/3-
&.S#$0#%$-%./%)20-)$0'^&#$,)3-
2*.%)39*)$--'/3-*.^9$0/)$$
)$0'^&#$,)3
8*.q)%0-2&'/-923'0)
8*.1#0'^#-923'0)
5)2*.39%#^#-2*.7)/
>%'&)h92-%.(2&)0)3@-2*.%)$$)$-
1#/'&#E)3-'/3-7''0)3
8*.39%0#./-&.0-3)1#/)3
8)*1.*('/%)-7)*#1#%'0#./-'/3
)e0)*/'&-7''0#./-%.(2&)0)3
A'*c)0#/S-2*)2'*)3
")7#%)-('$0)*-*)%.*3
O)*0#1#%'0#./-('*c$-S*'/0)3
5)S9&'0.*4-1#&)$-./-2&'/
8'0)/0-'/3-&#%)/$#/S-#$$9)$-
%&)'*)3
W#/'&-2*.39%0-*#$c-$0'0)()/0
D'9/%,-'%0#7#0#)$-2&'//)3-#/-3)0'#&
8*.1#0'^#-%./1#*()3
")$#S/-S.'&$@-2*.39%0-7#$#./
A'*c)0-$#09'0#./-'$$)$$)3
+)%,/#%'&-*)'&#E'0#./-'$$)$$)3
`/#0#'&-2*.q)%0-2&'/
`/#0#'&-2*.1#0'^#-%,)%c
`")+"$$)%&")
>(5?,'%[
e"++5/+)
$"#(/%[
;&1+)1+):&#%):")/""?[ ;&1+)1+):&#%):"):#/%)%5
7#4"[);&")@"+%)'5/'">%
&#+)@""/)1?"/%101"?)#/?
1%)1+)0"#+1@$"[
;&")?"D"$5>7"/%)1+)
01/1+&"?[)J>"'101'#%15/+
&#D")@""/)7"%[
`")'#/)7#4")1%[)`")#(")
("#?B)%5)+"$$[
>0'*0 D'9/%,8.$0
D'9/%,5)7#)b
Manufacturing
C"+1</m5#$+
C"+1</E/>,%
C"+1</F,%>,%
e#,/'&C"'1+15/
35'&")C1#</5+%1'+);#/73*$:&*+-&)$,*0$:&''#-%7,)7<,+7&*$5+,*0,-0
;&1+)1+)
>(571+1/<[
Z1/?)5,%)75("
#/?)<"%)@#'4
%5),+[
;J
C1#</5+%1'+)J,77#(B
[ +,)-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-'/-#(2.*0'/0-S*.b0,-'/3-#//.7'0#./-3*#7)*-1.*-0,)-`g"-#/39$0*4
[ +,)-2*.%)$$-1.*-3)7)&.2()/0-.1-/.7)&-`g"-0)$0$-#$-%.(2&)e-'/3-*#$c4-'/3-*)a9#*)$-0,)-#/39$0*4-0.-#/0)*1'%)-b#0,-$0'c),.&3)*$-#/-'%'3)(#'@-0,)-8,'*('-#/39$0*4-'/3-%.(2'/#)$-1.%9$$)3-./-^#.('*c)*-3#$%.7)*4-'/3-3)7)&.2()/0?-O.&&'^.*'0#./-b#0,-.0,)*-#/39$0*4-$0'c),.&3)*$-#$-)$$)/0#'&-0.-0,)-`g"-#/39$0*4
[ A'#/0'#/#/S-0,)-%9**)/0-0)$0-2.*01.&#.-./-)e#$0#/S-$4$0)($-'/3-3)7)&.2#/S-'22&#%'0#./$-1.*-0,)$)-0)$0$-./-/)b-'/3-*)2&'%)()/0-$4$0)($-*)a9#*)$-$#S/#1#%'/0-#/7)$0()/0@-&#(#0#/S-0,)-19/3$-'7'#&'^&)-1.*-#/7)$0()/0-#/-/.7)&-0)$0$
[ O.(2'/#./-3#'S/.$0#%-0)$0$-'/3-0)$0$-^'$)3-./-^#.('*c)*$-9$)3-#/ 8,'*('-3#$%.7)*4-'/3-%&#/#%'&-3)7)&.2()/0-2*.S*'($-b#&&-%./0*#^90)-$#S/#1#%'/0&4-0.-0,)-2#2)&#/)-.1-/.7)&-`g"-0)$0$-#/-%.(#/S-4)'*$
[ 5.%,)-"#'S/.$0#%$-#$-%.((#00)3-0.-#//.7'0#./-0,*.9S,-0,)-()3#%'& 7'&9)-2*.7#3)3-^4-/.7)&-`g"-0)$0$-'/3-b.*c$-%&.$)&4-b#0,-'-b#3)-*'/S)-.1-2'*0/)*$-0.-'%,#)7)-0,#$
;V
35'&")m(5,>Differentiation through Personalised Healthcare
[ +,)*)-'*)-$0#&&-('/4-%,'&&)/S)$-0.-.7)*%.()-#/-^#.('*c)*-
3#$%.7)*4@-7''0#./-'/3-%.(()*%#'&#E'0#./-
[ `/-$2#0)-.1-0,)$)-%,'&&)/S)$@-5.%,)-#$-%.((#00)3-0.-
8)*$./'&#$)3 Q)'&0,%'*)-f ^)%'9$)-#0_$-c)4-0.-.9*-(#$$#./-.1-
3)7)&.2#/S-#//.7'0#7)-()3#%#/)$-'/3-3#'S/.$0#%$-1.*-0,)-
^)/)1#0-.1-2'0#)/0$-'/3-$.%#)04
[ "#'S/.$0#%$-%'2'^#�#)$-'/3-0)%,/.&.S#)$-2&'4-'-%*9%#'&-*.&)-#/
3#$%.7)*#/S-i-,'*7)$0#/S-^#.('*c)*$
[ Q'7#/S-"#'S/.$0#%$_ %'2'^#�#)$-#/0)*0b#/)3-0,*.9S,.90-'&&-
$0'S)$-.1-3*9S-3)7)&.2()/0-#$-'-$#S/#1#%'/0-'37'/0'S)
;I
=#$>**&4,+#$?#,)+"%,-#
